[go: up one dir, main page]

ZA200400313B - Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine. - Google Patents

Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.

Info

Publication number
ZA200400313B
ZA200400313B ZA200400313A ZA200400313A ZA200400313B ZA 200400313 B ZA200400313 B ZA 200400313B ZA 200400313 A ZA200400313 A ZA 200400313A ZA 200400313 A ZA200400313 A ZA 200400313A ZA 200400313 B ZA200400313 B ZA 200400313B
Authority
ZA
South Africa
Prior art keywords
bibn4096
migraine
treatment
combination
antimigraine drugs
Prior art date
Application number
ZA200400313A
Other languages
English (en)
Inventor
Henri Doods
Klaus Rudolf
Wolfgang Eberlein
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ZA200400313B publication Critical patent/ZA200400313B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200400313A 2001-08-17 2004-01-15 Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine. ZA200400313B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10139410A DE10139410A1 (de) 2001-08-17 2001-08-17 Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne

Publications (1)

Publication Number Publication Date
ZA200400313B true ZA200400313B (en) 2004-11-01

Family

ID=7695082

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200400313A ZA200400313B (en) 2001-08-17 2004-01-15 Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.

Country Status (22)

Country Link
EP (1) EP1420790B1 (no)
JP (1) JP2005503382A (no)
KR (1) KR20040027892A (no)
CN (1) CN1543347A (no)
AR (1) AR036265A1 (no)
AT (1) ATE304854T1 (no)
BR (1) BR0211970A (no)
CA (1) CA2454083A1 (no)
CO (1) CO5560577A2 (no)
DE (2) DE10139410A1 (no)
EA (1) EA200400253A1 (no)
EC (1) ECSP044979A (no)
ES (1) ES2250733T3 (no)
HR (1) HRP20040150A2 (no)
HU (1) HUP0401484A3 (no)
IL (1) IL159879A0 (no)
MX (1) MXPA04001364A (no)
NO (1) NO20041024D0 (no)
PL (1) PL365482A1 (no)
UY (1) UY27416A1 (no)
WO (1) WO2003015787A1 (no)
ZA (1) ZA200400313B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
EP1374870A1 (en) * 2002-06-24 2004-01-02 Rita Dobmeyer Medication for the treatment or prevention of migraine
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
JP2007533685A (ja) * 2004-04-20 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたｃｇｒｐアンタゴニストの使用
EP1744784A2 (en) * 2004-05-11 2007-01-24 Becton, Dickinson and Company Formulations of anti-pain agents and methods of using the same
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
CN102526031A (zh) * 2010-12-27 2012-07-04 湖南九典制药有限公司 一种鼻腔内使用的舒马普坦药物组合物及其制备方法
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004037B1 (ru) * 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Also Published As

Publication number Publication date
BR0211970A (pt) 2004-09-21
HRP20040150A2 (en) 2004-06-30
HUP0401484A2 (hu) 2004-12-28
DE60206289D1 (de) 2006-02-02
UY27416A1 (es) 2003-03-31
CO5560577A2 (es) 2005-09-30
AR036265A1 (es) 2004-08-25
MXPA04001364A (es) 2004-05-27
EP1420790A1 (en) 2004-05-26
IL159879A0 (en) 2004-06-20
PL365482A1 (en) 2005-01-10
ECSP044979A (es) 2004-04-28
ES2250733T3 (es) 2006-04-16
WO2003015787A1 (en) 2003-02-27
HUP0401484A3 (en) 2007-03-28
EA200400253A1 (ru) 2004-08-26
DE10139410A1 (de) 2003-02-27
ATE304854T1 (de) 2005-10-15
CA2454083A1 (en) 2003-02-27
CN1543347A (zh) 2004-11-03
DE60206289T2 (de) 2006-06-08
JP2005503382A (ja) 2005-02-03
KR20040027892A (ko) 2004-04-01
NO20041024D0 (no) 2004-02-16
EP1420790B1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
ZA200207650B (en) Absorbent structure and absorbent articles containing the absorbent structure.
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
IL174994A0 (en) Pyrimidin - 4 - yl - 3, 4 - thione compounds and their use in therapy
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
HK1061679A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-ibe derivatives, their preparation and their therapeutic use.
IL178402A0 (en) 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
AP2006003537A0 (en) Use of polypeptides of the cupredoxin family in cancer therapy.
ZA200408767B (en) Immunoconjugates for the treatment of tumours
MXPA03008739A (es) Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
ZA200703876B (en) 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
ZA200003236B (en) Combination therapy for the treatment of migraine.
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
AP2005003362A0 (en) Formulation and methods for the treatment of thrombocythemia.
ZA200210316B (en) Composition and its therapeutic use.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
PL370272A1 (en) Absorbent structure, and absorbent article containing the absorbent structure
MXPA03006099A (es) Articulo absorbente con agente de tratamiento fluido.
TWI365187B (en) 7-azaindoles and the use thereof as therapeutic agents
IL160722A0 (en) Aryloxypropylamines as chemosensitizing agents in the treatment of cancer
MXPA03008393A (es) Derivados de guanidina biciclicos y usos terapeuticos de los mismos.
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.